CMS Home Use of Oxygen in Approved Clinical Trials — NCD 312 Policy Update (2026)

CMS has modified National Coverage Determination 312 (NCD 312), governing home oxygen use for Medicare beneficiaries enrolled in approved clinical trials. This update, effective March 12, 2026, reinforces coverage requirements for a narrow but clinically significant patient population: those with borderline hypoxemia enrolled in NHLBI-sponsored trials. If your practice or DME supplier serves patients in these trials, here's exactly what this policy means for your billing team.

What CMS NCD 312 Covers — Home Oxygen in Clinical Trials

The Centers for Medicare & Medicaid Services covers home oxygen under NCD 312 for Medicare beneficiaries who fall into a specific physiologic gray zone: arterial oxygen partial pressure (PaO₂) measurements from 56 to 65 mmHg, or oxygen saturation (SpO₂) at or above 89%. This is a critical distinction from the standard home oxygen NCD.

Under the standard home oxygen coverage rules (NCD 240.2 and NCD 310.1), patients typically need a PaO₂ at or below 55 mmHg or SpO₂ at or below 88% to qualify. NCD 312 exists precisely for the population that falls above those standard thresholds — patients who may still benefit from supplemental oxygen but for whom the evidence base is less definitive.

Coverage is conditional on two non-negotiable requirements:

1. The beneficiary must be an enrolled subject in a clinical trial approved by CMS
2. That trial must be sponsored by the National Heart, Lung & Blood Institute (NHLBI)

If either condition isn't met, the claim doesn't qualify under this NCD.

Medical Necessity Criteria Under CMS NCD 312

CMS is explicit about what the evidence supports here. The policy acknowledges that medical literature documents both health benefits and serious adverse events associated with supplemental oxygen use. That dual recognition — benefit and risk — is why CMS restricts this coverage to a controlled clinical trial setting rather than opening it to all patients with borderline hypoxemia.

The specific thresholds that trigger eligibility under NCD 312 are:

Documentation of these measurements is essential. Billers should expect payers and auditors to request lab values confirming the patient falls within this range — not below the standard NCD threshold, and not above the clinical trial eligibility ceiling.

How NCD 312 Relates to Standard Home Oxygen Coverage

This is a point of frequent confusion for billing teams, and the policy addresses it directly. NCD 312 does not alter Medicare coverage for home oxygen services provided outside the context of approved clinical trials. Those claims continue to be governed by:

• NCD 240.2 — General home oxygen coverage
• NCD 310.1 — Additional home oxygen criteria

Think of NCD 312 as a supplemental coverage pathway, not a replacement. A patient who qualifies under NCD 240.2 or 310.1 on their own merits doesn't need to be in a clinical trial to get home oxygen covered. NCD 312 only becomes relevant when a patient's oxygen levels fall in the 56–65 mmHg PaO₂ range — the gray zone that wouldn't qualify under standard rules.

Billing the wrong NCD for a patient's situation is a fast path to denial or, worse, a compliance exposure. Make sure your team understands which NCD applies to each claim.

Prior Authorization and Claims Processing

The policy does not specify a prior authorization requirement under NCD 312 itself. However, given that coverage is conditioned on enrollment in a CMS-approved, NHLBI-sponsored trial, the de facto documentation requirement is substantial. You'll need to retain:

• Proof of active enrollment in the specific CMS-approved clinical trial
• Documentation of the qualifying PaO₂ or SpO₂ measurements
• The treating physician's order for home oxygen
• Confirmation that the sponsoring entity is NHLBI

Claims processing instructions are governed by Transmittal 961 (Medicare Claims Processing). Billing teams should reference that transmittal for specific claim submission requirements. The CMS Coverage with Evidence Development (CED) page for home oxygen in COPD also serves as a cross-reference resource for this policy.

Affected Codes

This policy does not list specific CPT or HCPCS codes. CMS NCD 312 does not enumerate billable codes within the policy document itself. For the applicable HCPCS codes used to bill home oxygen and oxygen equipment under the DME benefit category, reference your DME MAC's local coverage articles (LCAs) associated with home oxygen, and the claims processing instructions in Transmittal 961.

Billing teams should also consult the related NCD cross-references (240.2 and 310.1) for code-level guidance on standard home oxygen billing.

What Your Billing Team Should Do